PRI 724

Drug Profile

PRI 724

Alternative Names: PRI-724

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer PRISM Pharma Co; Syneos Health; Tokyo Metropolitan Komagome Hospital
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Phase I Hepatic fibrosis; Pancreatic cancer; Solid tumours

Most Recent Events

  • 04 Jan 2018 inVentiv Health has merged with INC Research to form Syneos Health
  • 13 Apr 2017 University of Southern California withdraws prior to enrolment the phase II PREMIER trial for Colorectal cancer in USA (NCT02413853)
  • 30 Dec 2016 Prism Pharma completes a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) and Chronic myeloid leukaemia (Second-line therapy or greater) in USA (NCT01606579)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top